If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the ...

Please provide your email address to receive an email when new articles are posted on . All the allergists and immunologists who responded said they collaborate with gastroenterologists. 43% of ...

"Patients who are unable to function optimally in their daily life—in medical parlance, this would be those with poor performance status—really appear to be at greater risk of acute esophagitis during ...

Adults with high esophageal hypervigilance and anxiety and worse esophageal function prior to achalasia treatment experienced ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of the ...

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months ...

If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 inflammation that impacts the ...

Rationale To date, the exact significance of esophageal eosinophilia requires careful clinical consideration. Traditionally, this finding has been attributed solely to peptic injury, but with the ...